Research Progress in Immunosuppressive Tumor Microenvironment of Gastrointestinal Cancer

LI Yu-ting, TAN Xiang-yu, HUANG Liu-na, MA Li-xiang, FU Li

Abstract

Gastrointestinal (GI) cancer, a common malignant tumor with a high incidence in China, is showing a trend of rising incidence and is afflicting increasingly younger patients. Meanwhile, there have been constant development and innovations in new therapeutic technologies, among which, immunotherapy is now leading in a new era in the treatment of GI cancer. However, the complexity and diversity of immunosuppressive tumor microenvironment (TME) bring many obstacles to the immunotherapy of solid tumors in the GI tract. In this paper, focusing on solid tumors in the GI tract, we reviewed the main factors affecting the formation of immunosuppressive TME, and summarized strategies for targeted immunosuppressive TME-based therapies. Moreover, we analyzed the synergistic mechanism of various combination immunotherapies and reported on the latest progress in and future direction of immunotherapy for GI cancer, intending to provide new perspectives for treating solid tumors in the GI tract with immumotherapy.

 

Keywords: Gastrointestinal cancer, Immunosuppressive tumor microenvironment, Immunotherapy, Anti-tumor therapy

 

Full Text:

PDF


References


SHALAPOUR S， KARIN M. Cruel to be kind: Epithelial, microbial, and immune cell interactions in gastrointestinal cancers. Annu Rev Immunol， 2020，38: 649–671.

SUNG H， FERLAY J， SIEGEL R L， et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin，2021，71(3): 209–249.

QUANTE M， VARGA J， WANG T C， et al. The gastrointestinal tumor microenvironment. Gastroenterology，2013，145(1): 63–78.

JOYCE J A， FEARON D T. T cell exclusion, immune privilege, and the tumor microenvironment. Science，2015，348(6230): 74–80.

BARKER H E， PAGET J T， KHAN A A， et al. The tumour microenvironment after radiotherapy: Mechanisms of resistance and recurrence. Nat Rev Cancer，2015，15(7): 409–425.

HANAHAN D， WEINBERG R A. Hallmarks of cancer: The next generation. Cell，2011，144(5): 646–674.

ZHANG Y， XU J， ZHANG N， et al. Targeting the tumour immune microenvironment for cancer therapy in human gastrointestinal malignancies. Cancer Lett，2019，458: 123–135.

DAVERN M， DONLON N E， POWER R， et al. The tumour immune microenvironment in oesophageal cancer. Br J Cancer，2021，125(4): 479–494.

BINNEWIES M， ROBERTS E W， KERSTEN K， et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med，2018，24(5): 541–550.

NAGARSHETH N， WICHA M S， ZOU W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol，2017，17(9): 559–572.

OLLAURI-IBÁÑEZ C， AYUSO-ÍÑIGO B， PERICACHO M. Hot and cold tumors: is endoglin (cd105) a potential target for vessel normalization? Cancers (Basel)， 2021， 13(7): 1552[2021-12-20]. https://doi.org/10.3390/cancers13071552.

GAO H， MA J， CHENG Y， et al. Exosomal transfer of macrophage-derived miR-223 confers doxorubicin resistance in gastric cancer. Onco Targets Ther，2020，13: 12169–12179.

SAHAI E， ASTSATUROV I， CUKIERMAN E， et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer，2020，20(3): 174–186.

BIFFI G， TUVESON D A. Diversity and biology of cancer-associated fibroblasts. Physiol Rev，2021，101: 147–176.

MORTEZAEE K. Enriched cancer stem cells， dense stroma， and cold immunity: Interrelated events in pancreatic cancer. J Biochem Mol Toxicol， 2021， 35(4): e22708[2021-12-20]. https://doi.org/10. 1002/jbt.22708.

ERIN N， GRAHOVAC J， BROZOVIC A ， et al. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resist Updat， 2020， 53: 100715[2021-12-20]. https://doi.org/10.1016/j.drup.2020.100715.

LIN C C， LIAO T T， YANG M H. Immune adaptation of colorectal cancer stem cells and their interaction with the tumor microenvironment. Front Oncol， 2020， 10: 588542[2021-12-20]. https://doi.org/10. 3389/fonc.2020.588542.

LIAO T T， LIN C C， JIANG J K， et al. Harnessing stemness and PD-L1 expression by AT-rich interaction domain-containing protein 3B in colorectal cancer. Theranostics，2020，10(14): 6095–6112.

HUI E， CHEUNG J， ZHU J， et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science，2017，355(6332): 1428–1433.

ZHAO H K， WU L， YAN G F， et al. Inflammation and tumor progression: Signaling pathways and targeted intervention， Signal Transduct Target Ther， 2021， 6(1): 263[2021-12-20]. https://doi. org/10.1038/s41392-021-00658-5.

RAHMA O E， HODI F S. The intersection between tumor angiogenesis and immune suppression. Clin Cancer Res，2019，25(18): 5449–5457.

FLEMING C， MORRISSEY S， CAI Y， et al. γδ T cells: Unexpected regulators of cancer development and progression. Trends Cancer，2017， 3(8): 561–570.

HUANG T X， TAN X Y， HUANG H S， et al. Targeting cancer-associated fibroblast-secreted WNT2 restores dendritic cell-mediated antitumour immunity. Gut， 2021: gutjnl-2020-322924[2021-12-20]. http://dx.doi.org/10.1136/gutjnl-2020-322924.

GONÇALVES-RIBEIRO S， DÍAZ-MAROTO N G， BERDIEL-ACER M， et al. Carcinoma-associated fibroblasts affect sensitivity to oxaliplatin and 5-FU in colorectal cancer cells. Oncotarget，2016，7(37): 59766–59780.

NAKAMURA K， YAGUCHI T， OHMURA G， et al. Involvement of local renin-angiotensin system in immunosuppression of tumor microenvironment. Cancer Sci，2018，109(1): 54–64.

HAM I H， OH H J， JIN H， et al. Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer. Mol Cancer， 2019， 18(1): 68[2021-12-20]. https://doi.org/10.1186/s12943-019-0972-8.

XIANG X N， WANG J G， LU D， et al. Targeting tumor-associated macrophages to synergize tumor immunotherapy. Signal Transduct Target Ther， 2021， 6(1): 75[2021-12-20]. https://doi.org/10.1038/s41392-021-00484-9.

LI X， YAO W， YUAN Y， et al. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. Gut，2017，66(1): 157–167.

ALDINUCCI D， CASAGRANDE N. Inhibition of the CCL5/CCR5 axis against the progression of gastric cancer. Int J Mol Sci， 2018， 19(5): 1477[2021-12-20]. https://doi.org/10.3390/ijms19051477.

SUAREZ-CARMONA M， CHAORENTONG P， KATHER J N， et al. CCR5 status and metastatic progression in colorectal cancer. Oncoimmunology， 2019， 8(9): e1626193[2021-12-20]. https://doi. org/10.1080/2162402X.2019.1626193.

OKUGAWA Y， TOIYAMA Y， ICHIKAWA T， et al. Colony-stimulating factor-1 and colony-stimulating factor-1 receptor co-expression is associated with disease progression in gastric cancer. Int J Oncol，2018， 53(2): 737–749.

HIAM-GALVEZ K J， ALLEN B M， SPITZER M H. Systemic immunity in cancer. Nat Rev Cancer，2021，21(6): 345–359.

LIMAGNE E， EUVRARD R， THIBAUDIN M， et al. Accumulation of mdsc and Th17 cells in patients with metastatic colorectal cancer predicts the efficacy of a folfox-bevacizumab drug treatment regimen. Cancer Res， 2016，76(18): 5241–5252.

ZHANG X， SHEN L， LIU Q， et al. Inhibiting PI3 kinase-γ in both myeloid and plasma cells remodels the suppressive tumor microenvironment in desmoplastic tumors. J Control Release，2019，309: 173–180.

ZAPPASODI R， SERGANOVA I， COHEN I J， et al. CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours. Nature，2021， 591(7851): 652–658.

KANIKARLA P， HAYMAKER C， PARRA E R， et al. Pilot clinical trial of perioperative durvalumab and tremelimumab in the treatment of resectable colorectal cancer liver metastases. Clin Cancer Res，2021， 27(11): 3039–3049.

ZHANG L， SUN L， ZHOU Y， et al. Association of survival and immune-related adverse events with anti-PD-1/PD-l1 and anti-CTLA-4 inhibitors， alone or their combination for the treatment of cancer: A systematic review and meta-analysis of 13 clinical trials. Front Oncol， 2021， 11: 575457[2021-12-20]. https://doi.org/10.3389/fonc.2021.575457.

CHAUVIN J M， ZAROUR H M. TIGIT in cancer immunotherapy. J Immunother Cancer， 2020， 8(2): e000957[2021-12-20]. http://dx.doi.org/10.1136/jitc-2020-000957.

QI Y， CHEN L， LIU Q， et al. Research progress concerning dual blockade of lymphocyte-activation gene 3 and programmed death-1/programmed death-1 ligand-1 blockade in cancer immunotherapy: Preclinical and clinical evidence of this potentially more effective immunotherapy strategy. Front Immunol， 2021， 11: 563258[2021-12-20]. https://doi.org/10.3389/fimmu.2020.563258.

ABDUL-LATIF M， TOWNSEND K， DEARMAN C， et al. Immunotherapy in gastrointestinal cancer: The current scenario and future perspectives. Cancer Treat Rev， 2020， 88: 102030[2021-12-20]. https://doi.org/10.1016/j.ctrv.2020.102030.


Refbacks

  • There are currently no refbacks.